HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Purple Biotech (NASDAQ: PPBT - Get Free R

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

ADAR1 Capital Management LLC acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:

Biotech has been hot in 2026. The sector, tracked by the SPDR S&P Biotech ETF, (XBI +1.44%) is up 39

Wall Street analysts changed outlook on top names. Check all rating changes, including upgrades/down

Wall Street analysts upgraded PGR, MRK, EPR and initiated coverage on BEKE and IONS. Check analyst r

Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that n

Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and pri

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Chec

BMO Capital analyst David Lebowitz initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceutical

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

20,000 shares were purchased for a total value of ~$1.1 million across multiple execution windows. T

JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) Director Michael Hayden purchased 15,00

Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while

Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighe

Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Wall Street analysts changed outlook on top names: Barclays cut META price target, Needham boosted Q

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript

Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pi

Ionis Pharmaceuticals NASDAQ: IONS reported second-quarter revenue growth driven by commercial produ

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.43 per share versus the Zacks Cons

Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 mill

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that F

Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.42) per share which beat the an

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Guggenheim analyst Brad Canino maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lower

Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pha

Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen,

RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the first participant has been dosed

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS)

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweigh

Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and

Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy a

Citigroup analyst Eric Joseph maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers

Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 mill

Jefferies analyst Akash Tewari maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lower